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Introduction
Medical Genetics has a recent history in Brazil and started
out as a research program in Human Genetics during the
1950s, mainly by a shift in work of Brazilian scientists from
genetic studies conducted on drosophila melanogaster to this
new emerging field of research, following a worldwide ten-
dency (Otto and Frota-Pessoa 1975; Beiguelman 2000). The
Department of Biology, currently Department of Genetics
and Evolutionary Biology, at the Institute of Biosciences,
University of S~ao Paulo, was one of the main pioneers in
this field, followed by other initiatives at the Federal Uni-
versities at Rio Grande do Sul and Parana (Otto and Frota-
Pessoa 1975; Beiguelman 2000). The importance of genetics
was recognized by the medical community only as of the
60 and onward, after the advent of human cytogenetics,
and with the introduction of Genetics as a subject in a few
medical schools (Beiguelman 2000). Nevertheless, Medical
Genetics still is regarded as an optional discipline in many
medical schools in Brazil.
The Brazilian population is highly heterogeneous and
admixed, as a result of five centuries of crossbreeding
among native Amerindians, Europeans settlers and immi-
grants, and sub-Saharan Africans, who were mostly
brought to this country during the slavery period. The
country’s diverse regions underwent slightly different col-
onization processes: the North region had a larger preser-
vation of indigenous people, the Northeast region had a
stronger history of African influence, while Europeans
colonized most of the South region (Alves-Silva et al.
2000; Pena et al. 2011). More recently, waves of Asian
immigration reached mainly the Southeastern region. This
trihybrid admixture process was strongly influenced by a
directional mating between European males and African
and Amerindian females during the colonization period,
as demonstrated by the use of sexual and mitochondrial
chromosome markers (Pena et al. 2009; Resque et al.
2010). In the last decade, the availability of genomic
ancestry informative markers (AIMs) has encouraged a
precise characterization of the contribution of each paren-
tal population. It has been shown that European ancestry
is evenly preponderant across the country; the African
contribution has reached the highest proportion in the
Northeast (~30.3%), followed in decreasing order by the
Southeast (~18.9%), South (~12.7%), and North
(~10.9%) regions, while the Amerindian contribution is
the highest in the North (~19.4%) region, and relatively
evenly spread across the other regions (Santos et al. 2010;
Pena et al. 2011). An unexpected high Amerindian contri-
bution is also found in semi-isolated communities
founded by African-slaves refugees, the “quilombos”
(Lopes Maciel et al. 2011; Kimura et al. 2013; Gontijo
et al. 2014). Our colonization history also accounts for
the high incidence of some diseases. For example, the
autosomal recessive (AR) sickle cell disease (SCD), one of
the most common monogenic disorder in Brazil
(Cancado and Jesus 2007; Lobo et al. 2014, Table 1), has
been attributed to the intense African slave trade that
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occurred between the 16th and 19th centuries (Aygun
and Odame 2012).
The Brazilian admixture, as briefly explained, consti-
tutes a good example of a population characteristic boost-
ing the research on Genetics in Brazil. Inbreeding in
Brazil played a similar role within this field. The cultural
diversity, socio-economic status, migration, population
density, urbanization, and permissive laws have histori-
cally influenced the heterogeneous degree of consanguine-
ous marriages across the country (Machado et al. 2013;
Freire-Maia 1957, Fig. 1A). Even though inbreeding has
been decreasing in all Brazilian regions in the past dec-
ades, large differences between Southern and Northeastern
populations still remain, with the coefficient of inbreeding
(f) 13 times higher in some Northeastern (f = 0.00395;
proportion of consanguineous marriage from 6% to 12%)
populations as compared to Southern (f = 0.0003) popu-
lations (Freire-Maia 1957, 1989; Brito et al. 2011; Weller
et al. 2012; Machado et al. 2013), where the frequency of
consanguineous marriage (<5%) is comparable to the
estimates found for most of the other countries around
the world (Hamamy et al. 2011).
It is widely accepted that consanguineous marriage is a
risk factor for AR and multifactorial inheritance disorders.
Indeed, Brazilian consanguineous families have been use-
ful study subjects for identifying pathogenic mutations
underlying AR disorders, some of them originally
described in Brazil, such as acheiropodia, Richieri-Costa-
Pereira syndrome and Spastic paraplegia, optic atrophy,
and neuropathy (SPOAN, Freire-Maia et al. 1975; Iana-
Table 1. Genetic disorders under federal clinical protocols and guidelines for treatment including those from the newborn screening.
Disease Treatment
Ministry of Health
official programs
updated
Overall estimated
prevalence3
Included in newborn screening
Congenital adrenal hyperplasia Replacement hormone
medication
2010 1:7500–1:17,0914 (Brazil)
Congenital Hypothyrodism1 Levothyroxine2 2010 1:3808 (Brazil)
Cystic fibrosis Pancreatic enzymes; dornase
alfa
2010 1:70005–1: 13,073 (Brazil)
Sickle cell anemia Hydroxyurea 2010 1:10006–1:3129 (Brazil)
Phenylketonuria Dietary supplement 2013 1:24,780 (Brazil)
Biotinidase deficiency Biotin2 – 1:61,0677
Not included in newborn screening
Gaucher Enzyme replacement 2011 1:57,0008
Hereditary angioedema Danazol 2010 1:10,000–1:50,0009
Hereditary ichthyosis Retinoid 2010 1:4000 males (X linked form –
Germany)10
Osteogenesis Imperfecta Bisphophonates 2013 0.74:10,00011
Primary immunodeficiencies: antibody
deficiencies
Immunoglobulin 2007 0.12:100,00012
Turner syndrome Growth hormone 2010 1:1500–1:2500 females13
Wilson disease Chelation therapy, zinc
acetate
2013 1:30,00014
1Included in the newborn screening despite not being a genetic disorder.
2The medication is available in SUS, although there is no clinical protocol established.
3Brazilian Society of Newborn Screening (SBTN). In general, it was used data from the SBTN; prevalence estimates, however, varies across different
data sets.
4Silveira et al. (2008), Pezzuti et al. (2014).
5Raskin et al. (2008).
6Cancado and Jesus (2007).
7Wolf (1991).
8Meikle et al. (1999).
9Bork et al. (2003).
10Traupe et al. (2014).
11Prevalence based on South America countries (Barbosa-Buck et al. (2012)).
12Leiva et al. (2007).
13Saenger (1996).
14Bachmann et al. (1991).
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kiev et al. 2001; Macedo-Souza et al. 2005; Guion-Alme-
ida et al. 2009; Lines et al. 2012; Favaro et al. 2014), in
addition to others already described, such as Knobloch
syndrome (Sertie et al. 2000). Still, high rates of inbreed-
ing were recently reported to increase prevalence of some
rare AR disorders, such as mucopolysaccharidoses and
short stature, among others, in small Brazilian villages
(Salvatori et al. 1999; Costa-Motta et al. 2011). Recently,
National Institute of Populational Genetics (INAGEMP)
has launched a census concerning clusters of genetic dis-
orders in Brazil. Preliminary data list more than 100 small
villages with a likely higher prevalence of a specific disor-
der. At a national level, however, the degree of inbreeding
in Brazil has never been associated with increased overall
prevalence of AR disorder. The impact of inbreeding rate
in the etiology of complex disorders in the Brazilian pop-
ulation is still quite unexplored. Nevertheless, it has been
shown to confer increased risk for hypertension in qui-
lombos (Kimura et al. 2012), but not for nonsyndromic
cleft lip and palate (Brito et al. 2011).
The population admixture has always posed a challenge
to the gene mapping studies of complex traits in Brazil,
including pharmacogenomic studies, particularly when
designing case–control studies, which are prone to pro-
duce spurious association in the presence of population
structure. Accordingly, AIMs have proven to be useful for
inferring the putative biogeographic ancestry of individu-
als, estimating the ancestry proportions of admixed indi-
viduals and populations (Shriver et al. 1997; Halder et al.
2008; Pena et al. 2011; Pereira et al. 2012; Suarez-Kurtz
et al. 2012; Manta et al. 2013), correcting case–control
studies for stratification bias (Brito et al. 2012a,b; Bag-
ordakis et al. 2013), and performing admixture mapping
approaches. Many of such studies have benefited from
AIM panels built by Brazilian research groups, focused
specifically on discriminating Brazilian parental popula-
tions (Bastos-Rodrigues et al. 2006; Santos et al. 2010;
Brito et al. 2012a; Manta et al. 2013). In addition, in an
ethnically admixed population, it is possible to evaluate
the impact of certain at-risk alleles on the occurrence of
some disorders or to drug response among different
ethnicities simultaneously, under similar environmental
and socio-economical conditions (Suarez-Kurtz et al.
2014).
Brazil, with 26 states (Fig. 1A), is the world’s 5th larg-
est country in area (8,515,767 km2) and population
(199,242,462 million individuals; IBGE, 2012). The age
profile still remains as that of a young country, with 25%
of the population under 15 years old and just 7% over
65 years old. Life expectancy at birth is estimated as
73.8 years old. Despite presenting the 7th largest gross
domestic product (GDP), it ranks 61st and 85th in GDP
per capita and in human development index (0.73),
respectively (IBGE, 2012; reviewed in Acosta et al. 2013;
World Bank, 2014, data.worldbank.org), reflecting an out-
standing social inequality. As a related example, Brazil
still has a high infant mortality rate, but it varies consid-
erably across the country (Fig. 1B). On behalf of policies
with impact on sanitation and health, this rate has pro-
gressively decreased, and as part of the Millenium Devel-
opment Goals from the United Nations (UN), Brazil
reached the goal of decreasing the mortality rate to 2/3 of
the one observed in 1990, 2 years before the deadline, set
for 2015 (United Nation Development Programme,
2014). In this scenario, congenital malformations have
(B)
(A)
Figure 1. Inbreeding and Infant mortality rate across Brazil; (A)
Inbreeding occurrence in Brazil, adapted from Salzano and Freire-Maia
1967. The diameter of black dots are proportional to the coefficient
of inbreeding (f). According to that study, Brazil has a high-inbreeding
zone, with f values between 0.007–0.01, spanning most of
Northeastern inland, a medium-inbreeding zone (f values between
0.002–0.005), in the Northeastern coast and some Central–Western
areas, and a low-inbreeding zone (f values below 0.001),
encompassing the Southern states and other sparse areas.; (B) Infant
mortality rate in Brazilian regions (per 1000), according to the 2010
Census data of Brazilian Institute of Geography and Statistics (IBGE).
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become the second most common cause of death in chil-
dren under 1 year of age surpassing infectious diseases,
and represents more than 15% of the total number of
infant deaths since 2000 (Fig. 2; DATASUS, tabnet.data-
sus.gov.br). This data highlight the increasing importance
of Genetics for the health of the Brazilian population.
In this manuscript, we focus on describing the genetic
services provided in the country, how they are working
and some of our laws with direct impact on the quality
of life of families with rare genetic disorders, as well as
including Federal government support for treatment of
some rare genetic disorders.
Health Care
The public unified health system (“Sistema Unico de
Saude” or SUS) serves the majority of the Brazilian popu-
lation. SUS was created by the Brazilian Federal Constitu-
tion in 1988 and it is organized by the Ministry of
Health, with subsystems in each Brazilian State and city.
SUS possibly represents the largest public health system
in the world, and includes most aspects of health care,
from outpatient care to organ transplantation, and pro-
poses guidelines to ensure full, universal and free-of-
charge medical access for the entire Brazilian population.
In addition to offering appointments, medical exams and
hospitalizations, the SUS also promotes immunization
campaigns, prevention and health monitoring, such as
food control and medicament registration (Brazilian
Ministry of Health, 2014). It covers few genetic services,
most particularly tests for genetic newborn screening, as
detailed below.
In addition to SUS, 25.9% of the Brazilian population
(49.2 million inhabitants) has some sort of private health
insurance coverage (private health care plans). This per-
centage is much higher in urban (29.7%) than in rural
areas (6.4%), and also higher in the Southeast/South
regions (35.6/30.0%) than in the North/Northeast regions
(13.3/13.2%) (IBGE, 2009). These companies are regu-
lated by a National Supplementary Health Agency (ANS),
a federal government organization established in 2000.
Guidelines for coverage of several laboratory procedures
for genetic diagnosis (genomic cytogenetics, biochemical
and molecular techniques, particularly sequencing, and
prenatal diagnostic tests) by the Insurance Companies
were issued in January 2014.
Genetic Services Provided
Genetic services started growing at research settings and
universities. Despite the progressive translation of genetic
research into a clinical field and efforts from the medical
community toward its recognition as a specialty in SUS,
only in 2014 did the Ministry of Healthy issue guidelines
for complete assistance to be given to individuals with
rare disorders (Policy of Rare Diseases, Box 1). Within
this context, in the multidisciplinary team, medical
Geneticists were contemplated as an integral part of it.
Hopefully, with these national actions, the scenario pre-
sented here will improve within the next decade.
Figure 2. Evolution of infant mortality (under 1 year old) by year, from 1980 to 2013. With the observed overall decrease in deaths caused by
different conditions, congenital malformations became the second cause of infant mortality in Brazil (DATASUS).
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Box1 The National Policy for Rare Diseases* in Brazil,
defines guidelines for offering treatment to individuals
affected by rare diseases in the public unified health
system (Sistema Unico de Saude, SUS). It arose as a
consequence of a great effort and pressure from citi-
zens, aiming at reducing mortality and morbidity for
individuals with rare diseases. The project defines an
annual plan of action and financial and logistical sup-
port, and envisages the establishment of a national
database (important for facilitating the access to high
cost drugs, genetic tests, for instance) and the creation
of reference treatment centers. These centers should
be able to evaluate patients, perform genetic testing
procedures, diagnose, treat and offer genetic counsel-
ing (Diario Oficial da Uni~ao – ISSN 1677-7042no. 30,
12 February 2014, section 1, pages 44–55).
*The policy adopted the same definition of World
Health Organization for rare diseases affecting 65 out
of 100,000 individuals.
Clinical services
Most public centers and care services related to the field of
clinical genetics are usually located in State capitals, and
concentrated in the Southeast and South of Brazil. They are
usually integrated with public universities, teaching hospi-
tals – some of them with excellence in specific areas such as
Inborn Errors of Metabolism (IEM) within the Hospital
das Clı´nicas de Porto Alegre (HCPOA), at Universidade
Federal do Rio Grande do Sul - or hospitals specialized in
specific disorders, such as the Hospital for Rehabilitation of
Craniofacial Anomalies – Bauru, Universidade de S~ao
Paulo. These services are responsible for the medical care of
thousands of individuals and families annually and in the
case of HCPA, as well as for providing biochemical and
enzymatic assays for the diagnosis of IEM for any patient in
Brazil. These genetic services are usually regarded as refer-
ence centers at the regional or national level. There is, how-
ever, great difficulty in accessing them as there are no
official databases.
According to a census conducted in 2003 for mapping
public medical genetic services, medical genetic clinical
care was offered at 48 institutions in Brazil, and 33 of
them were somehow integrated with a genetic laboratory
(Horovitz 2003). More recent data show that new genetic
services are being implemented (96 clinical genetic ser-
vices: 66 in the Southeast/South regions and 21 in North-
east states), particularly in states previously devoid of
such kind of assistance. Nevertheless, some Brazilian
States (Amapa, Roraima, Rondo^nia and Tocantins, all of
them located in the North region), still lacked specialized
care in Genetics (Fig. 3).
Despite the increase in medical genetic care, the current
number of public services offered and specialized person-
nel in medical and human genetics are far below the
needs of the country (Horovitz et al. 2013; Acosta et al.
2013).
Genetic laboratories
The availability of publically funded diagnostic exams for
genetic diseases follows a distribution pattern similar to
that of the public medical genetic services in Brazil, with
a higher concentration in the South-Southeast regions
(Horovitz 2003; Marques-de-Faria et al. 2004). Today,
there is no logical referenced flow for public diagnostic
tests and public clinical services around the country,
instead informal agreements have been made between
them.
A research study conducted on public genetic services
in Brazil (Horovitz 2003, 2003) showed that diagnostic
genetic tests were available in 47 of 66 genetic services,
Figure 3. Updated graphic representation of clinical genetic services
in Brazil (2012), with aggregated information from the census by
Horovitz (2003), outpatient information system from the Ministry of
Health and Brazilian Society of Medical Genetics, plus updated
information on new clinical genetic services (presentation of abstracts
at meetings of the Brazilian Society of Medical Genetics and personal
communications between the years 2003 and 2009). There is no
reference to any type of care in the speciality in the states of Amapa
(AP), Roraima (RR), Rondo^nia (RO) and Tocantins (TO).
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which are partly funded by SUS. Among them, 83%
offered conventional cytogenetics, 55% high-resolution
cytogenetics, 32% fluorescent in situ hybridization, 36%
tests for IEM, and 32% prenatal diagnosis. About 50% of
them also used molecular biology techniques for several
groups of diseases, including mental retardation, dysmor-
phic syndromes, cancer predisposition, infertility, and
neuromuscular and metabolic diseases, among others.
The use of molecular biology techniques has grown and
some groups have implemented the use of next genera-
tion sequencing (NGS) technology, but most of them
were introduced by research and funded projects. Their
permanence and use for diagnosis, however, has been
challenged in many institutions as a result of lack of
funding. However, this picture will change after the
implementation of the policy for rare diseases, as
specialized services will be encouraged to provide full
care, including laboratory diagnosis, with the provision of
specific Federal funding (Brazilian Ministry of Health,
2014).
In the private setting, genetic tests are more readily
available, with the promptness of the investigation and
access to complementary exams the main difference
between private care and consultations in public hospitals.
All kinds of testing procedures are available in the private
sector, including not only the diagnosis of genetic disor-
ders of affected individuals, but also pre-implantation
genetic diagnosis, prenatal diagnosis, non-invasive prena-
tal diagnosis (NIPT), expanded newborn screening, pre-
dictive testing, and pharmacogenetics. The private sector
usually makes use of the most advanced techniques,
including the recent availability of exome and genome
sequencing which became available in a few private labo-
ratories in some of the State Capitals of Brazil. Nonethe-
less, despite the availability of these tests, samples are
sometimes sent abroad for processing and health insur-
ance companies do not always cover the costs.
Professionals in Genetics
Medical genetics residency
The medical practice in genetics in the country, as men-
tioned earlier, has had a recent onset, particularly when
compared to other medical specializations. Although the
first service that offered residency in Medical Genetics
was established in 1977 in the Hospital of the Medical
School of Ribeir~ao Preto, University of S~ao Paulo,
Ribeir~ao Preto, SP, only in 1983 did the Federal Council
of Medicine regulate this Medical specialization. The Bra-
zilian Society of Clinical Genetics (Sociedade Brasileira de
Genetica Clınica – SBGC), later renamed as Brazilian
Society of Medical Genetics (Sociedade Brasileira de Gen-
etica Medica – SBGM), was established in 1986 at the
32nd National Genetics Meeting and the 38th Annual
Meeting of the Brazilian Society for the Progress in Sci-
ence (Sociedade Brasileira para o Progresso da Cie^ncia)
(Brunoni 1997). The program in Medical Genetics,
approved by the National Medical Residence Committee,
is a 3-year training residency program. Eligible candidates
are individuals who have received a medical degree. The
program includes training in specific areas of Internal
Medicine and Pediatrics, in addition to Medical Genetics.
State or Federal funds support the majority of residency
training in Brazil. At the end of the program, the resi-
dent receives a specialization title issued by the Ministry
of Education. In turn, the Brazilian Medical Genetics
Society (SBMG) offers board certification in Medical
Genetics. It is recognized by the Brazilian Medical Associ-
ation and the Federal Council of Medicine, and com-
prises a theoretical test, analysis of curriculum and an
interview.
The residency program in Medical Genetics is available
in only five Brazilian States (Minas Gerais, Bahia, S~ao
Paulo, Rio Grande do Sul, Rio de Janeiro) and in the
Federal District. A total of 11 service providers offer 19
spots available for residents yearly. Based on registration
in SBGM, there are currently less than 300 Medical
Geneticists in the whole country.
Genetic counseling
Genetic counseling is usually offered by medical geneti-
cists and health professionals from different back-
grounds, at genetic service providers usually associated
with academia. The Biology Federal Council (“Conselho
Federal de Biologia”) recognizes genetic counseling as a
field of specialization, but SUS does not recognize these
professionals or other nonmedical professionals as an
integral part of a multidisciplinary healthcare team. With
the recent guidelines established for integral attention
given to rare disorders (Brazilian Ministry of Health,
2014; Box 1), after claims made by many professional
categories and scientific societies, the national resolution
will formally include nonmedical geneticists trained in
Genetic Counseling in public health teams for providing
genetic counseling. Accordingly, several courses in
Genetic Counseling for health professionals are being
formulated and will soon be implemented (Institute of
Biosciences of the University of Sao Paulo as a profes-
sional postgraduate program - M. R. Passos-Bueno, pers.
comm.; Brazilian Society of Medical Genetics, 2014).
These programs will allow the training of a greater
number of professionals, whom, together with the medi-
cal geneticists, will ensure better access to genetic ser-
vices offered across the country.
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The Burden of Birth Defects and
Genetic Disorders
The total birth prevalence of serious genetic congenital
disorders in Brazil was estimated by the March of Dimes
to be 57.2 per 1000 live births (Christianson et al. 2006).
When classifying by mode of inheritance, estimates of
defects per 1000 are as follows: 7 for dominant single
gene, 1.3 for X-linked and 3.9 for recessive; 3.6 for
chromosomal and 36.9 for congenital malformations in
general (Christianson et al. 2006). The birth prevalence of
neural tube defects has been estimated at 6390 new cases
per year (Christianson et al. 2006).
No registry of birth defects or genetic disorders is avail-
able in Brazil. There are, however, some instruments that
could provide some data. One of them is the field intro-
duced in 2000 (CEInfo (Coordenac~ao de Epidemiologia e
Informac~ao) 2011) for recording the presence of congeni-
tal malformation in the live-birth declaration (LD) – offi-
cial document issued by hospitals. Nevertheless, the
completion of this field is not mandatory, and conse-
quently, underreporting of congenital anomalies has fre-
quently been shown in several analyses (DATASUS;
Cunha et al. 2002; Guerra et al. 2008a,b).
Exposure to teratogens during pregnancy is an impor-
tant risk factor for these defects in Brazil. Studies have
shown that misoprostol, a synthetic analog of prosta-
glandin E1 originally used to treat peptic ulcers but
shown to increase the risk of Moebius syndrome and
limb transversal defects if taken in pregnancy (Gonzalez
et al. 1998; Dal Pizzol et al. 2006), still is widely used in
Brazil to induce illegal abortion. As a result of the high
prevalence of leprosy in Brazil, the use and prescription
of thalidomide has been approved in Brazil since 1965,
under a very restrictive regulation by the Federal Gov-
ernment (law no. 10.651, 2003). Nevertheless, births of
individuals with thalidomide syndrome were reported in
this century (Vianna et al. 2011). The use of alcohol in
early pregnancy seems to accounts for a large proportion
of birth defects, as well as intellectual disability in Brazil,
as suggested by the estimated incidence of 38.7/1000 live
births of fetal alcohol spectrum disorders in the city of
S~ao Paulo (Mesquita and Segre 2009). This scenario is
partially related to the Brazilian culture of self-medica-
tion and the possibility of purchasing several prescrip-
tion medications “over the counter”. A very positive
initiative was the establishment of the National System
of Information about Teratogen Agents (SIAT) in 1990
(Sch€uller-Faccini et al. 2001; Dal Pizzol et al. 2008)
which was set up to better educate the population con-
cerning the use of drugs and their possible teratogenic
effects. It is, however, funded by a university and
research grants.
The relevance of birth defects/genetic disorders in pub-
lic health has become increasingly prominent since 2000,
when the congenital malformations became the second
cause of deaths in children younger than 1 year old. Con-
genital anomalies also became accountable for 20% of the
deaths, exceeding the total sum between the 3rd and 4th
causes, which are, respectively, related to respiratory and
infectious diseases (DATASUS; Fig. 3). Birth defects/
genetic disorders account for more than one-third of the
total pediatric admissions in certain tertiary care hospitals
in Brazil (Horovitz 2003; Horovitz et al. 2005). An incre-
ment of the permanency and hospitalization cost for this
group of diseases can also be noticed (DATASUS, 2009).
This information reinforces the importance of the imple-
mentation of the new policy for rare diseases in Brazil
(Brazilian Ministry of Health, 2014; Box 1).
Genetic Newborn Screening
Genetic population screening has been performed in
Brazil only for newborns. It started with isolated initia-
tives in the 1970s and 1980s, without governmental
directions or policies (Carvalho et al.2007; Le~ao and
Aguiar 2008). In the 1990s, newborn screening became
mandatory for some diseases, and SUS started to fund
the tests needed for such procedures. Finally, in 2001,
it was formally established by the Ministry of Health,
became known as the National Newborn Screening Pro-
gram (Programa Nacional de Triagem Neonatal –
PNTN) and has been funded by the Federal govern-
ment since then. Its specific goals are to ensure equita-
ble access for all Brazilian newborns; organize State
screening networks; ensure therapy and follow-up for
each disorder detected; reduce morbidity and mortality;
provide guidelines to standardize regional services pro-
vided; and create and support National Newborn
Screening Database to collect epidemiological data. The
following diseases are screened by the program: phenyl-
ketonuria (PKU), congenital hypothyroidism (CH), SCD
and other hemoglobinopathies (SC), cystic fibrosis (CF),
and, recently included, biotinidase deficiency (BD) and
congenital adrenal hyperplasia (CAH) (Marques-de-Faria
2006; Diario Oficial da Uni~ao 12 December 2012, 54–
55). Such recommendation followed a rationale of pro-
gressive implementation phases (Phase I: PKU and CH,
Phase II: PKU, CH and SC; Phase III: PKU, CH, SC
and CF; Phase IV: BD and CAH), taking into account
existing inequalities in health care structure. The refer-
enced services for newborn screening are supposed to
ensure not only the screening process, but also diagnos-
tic confirmation and appropriate monitoring and treat-
ment of screened patients. Currently, there are 15
States in Phase III and 12 States in Phase IV of the
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program (Brazilian Ministry of Health). PNTN becomes
part of a social program named “Living without limit”
– National Plan for the Rights of Persons with Disabili-
ties, which integrates actions in various fields, focusing
on people with disabilities. The proposal is that the
PNTN include, in addition to the blood-tests, screening
for neonatal deafness and ophthalmologic evaluation.
By 2013, there were reference services registered by
PNTN in all Brazilian States, providing coverage for
80% of newborns (Brazilian Ministry of Health, 2013).
The program has shown good quality coverage, flexibil-
ity in the process, and also the possible integration
capability between the primary health care and refer-
ence centers. The PNTN is run by municipal and state
health offices; the global supervision is entrusted to the
technical advisory group, established and coordinated
by the Health Care Department of the Ministry of
Health (Marques-de-Faria 2006; Brazilian Ministry of
Health). A 10-year follow up study on the screening of
hemoglobinopathies conducted in the state of Rio de
Janeiro showed that early diagnosis and treatment of
newborns resulted in substantial improvements in sur-
vival and quality of life of Brazilian children with SCD
(Lobo et al. 2014). These results are quite encouraging
and similar studies should be conducted so as to evalu-
ate the effectiveness of the PTNT program in the health
of these affected individuals across the different regions
of the country.
The panel of diseases currently screened by the PTNT
(Table 1) still is modest when compared with the screen-
ing programs of some developed countries. Nevertheless,
PTNT represents the largest initiative carried out by SUS
in the area of genetics (Le~ao and Aguiar 2008). Expanded
neonatal screening can be alternatively performed by pri-
vate laboratories, which offer screening through mass
spectrometry for 30 rare treatable metabolic disorders at
least.
Data on the prevalence of specific single gene disorders
have become available thanks to the analysis conducted
by the newborn screening program (Table 1). It has been
shown that the incidence or prevalence of these diseases
varies across the country (Cancado and Jesus 2007; Silve-
ira et al. 2008; Stranieri and Takano 2009; Nunes et al.
2013). In some cases, they reflect the different propor-
tions of European, African or Amerindian contribution to
the population structure. For example, SCD was esti-
mated to have a prevalence of 1:1000 live births by
Cancado and Jesus (2007), but its prevalence was esti-
mated as 1:650 in the state of Bahia in the Northeast,
where African ancestry is the most preponderant, and of
1:13,000 in the Southern state of Rio Grande do Sul, with
a high contribution of European ancestry (Cancado and
Jesus 2007).
Clinical Protocols in SUS
The Ministry of Health has issued several clinical proto-
cols in an attempt at unifying the management of several
disorders. In 2011, a special commission (CONITEC) was
created with the aim to assist in the treatment as well as
in the incorporation, exclusion or alteration of health
technologies in the SUS. Today, 78 clinical protocols are
available, excluding here the ones for cancer treatment. In
this list, some genetic disorders are already contemplated
(Table 1). It is of note that enzyme replacement therapy
for Gaucher disease is contemplated and in 2011, 600
individuals were receiving the medication through the
SUS. In turn, as the goals of SUS are to provide full,
universal and free-of-charge medical access to the entire
Brazilian population, the Government has been facing an
increasing number of decisions from the Court of Law
favoring the payment of expensive medications not
considered as a regular medication by SUS.
Pregnancy Termination and Assisted
Reproduction
In Brazil, the legislation on this topic dates back to 1940
and it allows the physician to perform a pregnancy ter-
mination procedure only in cases in which the preg-
nancy imposes a life-threatening situation for the mother
or if the pregnancy is the result of rape. If a woman ter-
minates her pregnancy on her own or if the act is per-
formed with her knowledge, she and the medical
personnel responsible for the procedure could face
1–3 years in prison (according to Decreto-Lei no. 2848,
7 December 1940).
In April 2012, the Brazilian Supreme Court declared
that terminating a pregnancy where the fetus is diagnosed
with anencephaly is an anticipatory therapeutic act and
could not be included in the established rules (“articles
124, 126 and 128, items I and II, of the Penal Code”) reg-
ulating pregnancy termination. Accordingly, in May 2012,
the Federal Council of Medicine published recommenda-
tions for the physicians regarding the anticipatory thera-
peutic act in cases of unquestionable diagnosis of
anencephaly. In these situations, the pregnant woman has
the right to decide about the fate of her pregnancy with-
out a Court authorization.
Assisted reproduction has been performed for several
decades in Brazil, particularly in the private sector. How-
ever, there is no law regulating this procedure. In January
2011 (RESOLUTION CFM n 2013/13), the Federal Med-
ical Council implemented guidelines concerning this area.
The technique is not supposed to select embryos based
on the sex or other biological characteristic, except when
used to avoid an X-linked disorder. The number of
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embryos implanted is related to the age of the mother: up
to two embryos in mothers younger than 35 years old,
three embryos, in mothers between 36 and 39 years old
and four embryos in mothers between 40 and 50 years
old. All the embryos not implanted in the uterus should
be kept frozen and the parents should express their writ-
ten will concerning the fate of these embryos in case of
divorce, serious illness or death of one or both spouses or
whether they wish to donate them. The reproductive
technique can also be used for preventing and treating
genetic or inherited disorders. In both cases, the couple
must sign a written informed consent. Embryos kept
frozen for more than 5 years of age could be discarded.
In March 2005, a law (N 11.105) issued by the National
Bio Security Council (Conselho Nacional de Biossegu-
ranca – CTN-Bio) allowed the use of embryonic stem
cells in research and therapy provided by human embryos
produced by in vitro fertilization. For this purpose, the
embryos must be regarded as nonviable or kept frozen for
a minimum of 3 years and the parents must sign a
written informed consent.
Conclusions and Thoughts
The panorama of our 50 years of experience in human
and medical genetics in Brazil shows a heterogeneous set-
ting up of public and private genetic services across the
country, with better infrastructure and development in
the South and Southeast regions when compared to other
regions of the country.
The regulations concerning rare diseases established by
the Federal Government (Box 1) opened the possibility of
conducting accredited clinical and genetic testing. It is
now expected that network services will be established,
which will increase the capacity of work of the current
available trained professionals in genetics, who are
still too few in number to attend to all of the Brazilian
population.
The introduction of NGS will bring new perspectives in
diagnosis and ethical issues. Its application will certainly
reduce costs for establishing diagnosis, mainly of hetero-
geneous disorders, such as Noonan syndrome, Neuromus-
cular disorders, among several others, where the precise
diagnosis depends on several laboratorial exams and
analysis of several genes. Some Brazilian groups are cur-
rently implementing NGS facilities. As an example, the
Human Genome Center and Stem Cell (HUGH-CEL),
University of S~ao Paulo, offers a NGS panel containing
about 500 genes for 4 main groups of disorders (Neuro-
muscular/Neurodegenerative; Craniofacial/Skeletal dyspla-
sias; treatable forms of IEM and Hereditary forms of
Cancer). No guidelines have yet been formally established
for conducting clinical exome or genome testing, as well
as for informing incidental findings.
In summary, much has yet to be done to have public
genetic services organized in Brazil. A balance between
strengthening the genetic services already available and
the creation of new ones, particularly in the neglected
regions of Brazil, is a challenge that this new Federal Pol-
icy will face in the near future. Hopefully, planned and
implementation actions should be taken by the Brazilian
government together with specialists, such as scientists
and geneticists affiliated with the two main Brazilian
Genetic Societies (SBG and SBGM), and agents of rare/
genetic disease patient/parent organizations. These actions
will certainly have a significant impact on improving
health care for the Brazilian population and research on
medical genetics and genomics.
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